Aurelius SE & Co. KGaA

Earnings Release • Jul 21, 2015

News Details

Corporate | 21 July 2015 07:30

AURELIUS subsidiary ISOCHEM growing after reorientation

AURELIUS AG / Key word(s): Development of Sales

2015-07-21 / 07:30

---

AURELIUS subsidiary ISOCHEM growing after reorientation

– 30 percent sales growth in 2015

– Investments in new production facility

Munich, July 21, 2015 – The strategy of refocusing on the pharmaceutical business with an emphasis on customer-specific syntheses is bearing fruit for AURELIUS subsidiary ISOCHEM. The specialist for fine chemicals, that was taken over at the beginning of 2010 by AURELIUS, is recording considerable growth and clearly rising productivity. Numerous new products and a well-filled development pipeline should ensure a sustainably positive development for the company.

“As expected, our reorientation begun in 2011 has resulted in a noteworthy increase in sales and a new vitality in production and the development pipeline”, says Dr. Björn Schlosser, Vice President Operations at AURELIUS and responsible for the reorientation of ISOCHEM from the beginning. “Based on the figures for the first half of 2015, our core business with pharmaceutical customers will expand by approximately 30 percent this year. We are confident that this very positive development will continue.”

The main growth driver was the growing demand for ISOCHEM’s customer-specific synthesis products. The company, which is based in France and the United Kingdom, also exported considerably more to foreign countries and in particular was able to gain a larger share of the market and attract new customers in North America. “Our product and project portfolio never looked healthier: Since 2013, we have been developing around 15 new products every year. For the current year, we are planning the renewal of around 35 percent of the value of our overall product portfolio”, says ISOCHEM’s Head of Distribution and Business Development, Amélie Arboré.

The sales growth and the rising demand are also reflected in new jobs – in particular in research and development – and the expansion of the production facilities. A new Hastelloy rotating distillation unit with a daily capacity of more than half a tonne will tangibly stimulate important business with cGMP carbonyl chloride intermediate products for ISOCHEM.

ABOUT AURELIUS

AURELIUS is one of the leading European investment groups. From its offices in Munich, London, Stockholm and Madrid, AURELIUS acquires participations with development potential. Once under the AURELIUS umbrella, the acquisitions are given a long-term strategic orientation in order for them to fully develop their potential.

Currently, the AURELIUS Group consists of 20 subsidiaries with locations in Europe, Asia, and the U.S.A. These include numerous traditional consumer brands, services businesses and a number of industrial enterprises. Companies are acquired based on strict investment criteria without focusing on any particular industry. Shares of AURELIUS AG are listed in the m:access segment of the Munich Stock Exchange and are traded on all German stock markets under ISIN DE000A0JK2A8.

To find out more, visit www.aureliusinvest.com

CONTACT

Anke Banaschewski

Investor Relations & Corporate Communications

Phone +49 (89) 544799 – 0

Fax +49 (89) 544799 – 55

investor@aureliusinvest.de

---

2015-07-21 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Media archive at www.dgap-medientreff.de and www.dgap.de

---

379265  2015-07-21